source
- GSK allocates over $800 million to expand R&D and manufacturing hub in PennsylvaniaGSK announced it will invest more than $800 million to expand its presence in Pennsylvania, marking its second expansion in the state within two years. The funds will be used to build a new resear…
- Tortugas Neuroscience's obuprazine shows significant improvement in phase 2b schizophrenia trial in ChinaTortugas Neuroscience, a biotech founded by former Sage Therapeutics staff with $106 million in funding, reported positive data from a phase 2b study of its schizophrenia candidate obuprazine, lice…